Pharmacodynamics<unk>  acts as an agonist of the dopamine D2 receptor and as an antagonist of the serotonin 5-HT2A and 5-HT2B receptors, among other actions. As an antagonist of the 5-HT2B receptor,<unk>  is not associated with cardiac valvulopathy. + Site Affinity (Ki nM) Efficacy (Emax %) Action D1 28 ? ? D2S 0.81 39 Partial agonist D2L 1.1 0 Silent antagonist D3 1.0 36 Partial agonist D4 8.1 0 Silent antagonist D5 23 ? ? 5-HT1A 3.5 71 Partial agonist 5-HT1B 257 37 Partial agonist 5-HT1D 16 62 Partial agonist 5-HT2A 4.8 49 Partial agonist 5-HT2B 7.1 0 Silent antagonist 5-HT2C 48 0 Silent antagonist 5-HT7 8–42 ? ? α1A 3.5 0 Silent antagonist α1B 35 ? ? α1D 3.9 ? ? α2A 0.30 0 Silent antagonist α2B 0.45 0 Silent antagonist α2C 0.76 0 Silent antagonist α2D 1.5 ? ? β1 661 ? ? β2 20 ? ? H1 339 ? ? M1 >10,000 ? ? Notes: All receptors are human except α2D-adrenergic, which is rat (no human counterpart), and 5-HT7, which was guinea pig.
Terguride
Lumasiran
Eluxadoline
Metergoline
Acebutolol
Tolbutamide
Brinzolamide
Rolapitant